• SB-505124 Hydrochloride: Precision Tool for Fibrosis and Mec

  2026-07-27

  Discover how SB-505124 hydrochloride, a selective TGF-β/activin signaling inhibitor, advances fibrosis and mechanotransduction research with high specificity and favorable delivery. This article explores unique mechanistic and assay design insights not found elsewhere.

• Trichostatin A: Advanced Protocols for Epigenetic Regulation

  2026-07-27

  Unlock robust, reproducible epigenetic modulation with Trichostatin A (TSA) for oncology and differentiation workflows. Explore actionable protocols, troubleshooting insights, and the latest innovations bridging HDAC inhibition with real-time enzyme activity assays.

• Geneticin, G-418 Sulfate (SKU A2513): Reliable Selection and

  2026-07-26

  This article provides evidence-based guidance for using Geneticin, G-418 Sulfate (SKU A2513) to overcome common challenges in cell viability, selection, and antiviral assays. Integrating practical scenarios, literature data, and protocol optimization, we demonstrate how APExBIO's Geneticin enables reproducible, high-confidence results for biomedical research.

• Machine Learning Uncovers Novel Senolytics for Senescence Re

  2026-07-25

  The referenced study demonstrates how machine learning can efficiently identify new senolytic compounds by leveraging heterogeneous published datasets. This approach not only reduces screening costs but also expands the toolkit for targeting cellular senescence, with implications for cancer and age-associated disease research.

• Cepharanthine: Applied Workflows in Apoptosis and Disease Mo

  2026-07-24

  Cepharanthine, a biscoclaurine alkaloid, enables precise apoptosis modeling and immunomodulation in both cancer and endometriosis research. Its unique profile—validated in organoids and in vivo—translates to powerful experimental flexibility and clinical relevance.

• Ranolazine: Bridging Cardiac Metabolism and Translational In

  2026-07-24

  This thought-leadership article explores Ranolazine’s mechanistic role as an anti-ischemic agent, its impact on cardiac metabolism and relaxation, and its strategic value for translational researchers. Integrating recent advances in autophagy-innate immunity crosstalk and referencing both recent HBV mechanistic discoveries and advanced cardiac research workflows, this piece demonstrates how Ranolazine empowers novel experimental designs. It distinguishes itself by connecting metabolic modulation in cardiac ischemia with evolving research on cellular stress responses, providing actionable guidance and maturity-aware perspective for the translational research community.

• Cisplatin in Chemoresistance: Mechanisms, Models, and Innova

  2026-07-23

  Explore how Cisplatin (CDDP) advances cancer research through unique DNA crosslinking, apoptosis assays, and cutting-edge approaches to chemotherapy resistance. This article offers a new perspective on integrating molecular mechanisms with practical assay design.

• PARP7 Inhibition Restores IFN Signaling and Alleviates EAE i

  2026-07-23

  Xu et al. reveal that PARP7 mediates the autophagic degradation of STAT1/STAT2, suppressing type I interferon signaling and exacerbating experimental autoimmune encephalomyelitis (EAE) in mice. Pharmacological inhibition of PARP7 stabilizes STAT1/STAT2, enhances interferon responses, and relieves EAE symptoms, suggesting a new immunoregulatory target for multiple sclerosis research.

• Biotin-16-UTP: Precision RNA Labeling for Advanced Assays

  2026-07-22

  Biotin-16-UTP empowers sensitive, high-fidelity RNA labeling for detection, purification, and RNA-protein interaction studies. Its robust integration into in vitro transcription workflows advances both basic research and next-generation biosensor development.

• Iptacopan (LNP023): Applied Workflows for Complement Researc

  2026-07-22

  Iptacopan (LNP023) revolutionizes complement activation research with potent, selective inhibition of factor B, enabling precise dissection of alternative pathway mechanisms in both cellular and animal models. By integrating robust protocol parameters, troubleshooting strategies, and translational insights from the latest clinical studies, researchers can accelerate discovery and optimize outcomes in complement-mediated disease modeling.

• FerroOrange Fe²⁺ Fluorescent Probe: Advancing Live-Cell Iron

  2026-07-21

  FerroOrange, APExBIO’s Fe²⁺ fluorescent probe, sets the benchmark for real-time, live-cell intracellular iron detection. Its robust specificity, compatibility with modern imaging platforms, and proven performance in ferroptosis research empower precise, reproducible workflows even in complex models of iron metabolism.

• Carrier-Platin Nanotherapeutics: Rapid ROS-Mediated Cancer C

  2026-07-21

  Liu et al. introduce 'carrier-platin', a platinum-based nanotherapeutic that induces a rapid and non-classical cancer cell death via an intracellular ROS storm, distinct from apoptosis or ferroptosis. This innovation may overcome multidrug resistance in cancer, offering a new direction for ROS-driven chemotherapy with minimal systemic toxicity.

• Sulfo-NHS-LC-Biotin: Technical Parameters for Surface Biotin

  2026-07-20

  Sulfo-NHS-LC-Biotin enables stable, covalent biotin labeling of primary amines on cell surface proteins in aqueous conditions, addressing workflows that require selective, irreversible, extracellular modification. It is not recommended for intracellular or reversible biotinylation. Researchers should adhere to best practices for reagent handling and workflow setup to ensure consistent results.

• Fucoidan: Applied Oncology and Hepatoprotection Workflows

  2026-07-20

  Fucoidan, a sulfated α-L-Fucan, advances cancer and liver injury research with multifaceted workflows for apoptosis induction, immune modulation, and gut–liver axis protection. This guide translates the latest mechanistic breakthroughs into actionable protocols and troubleshooting strategies for reliable, reproducible results.

• Porcupine Inhibition as a Therapeutic Strategy for Scleroste

  2026-07-19

  This study demonstrates that pharmacological inhibition of porcupine (PORCN) effectively attenuates high bone mass and skeletal overgrowth in a Sost-deficient mouse model of sclerosteosis. The research establishes LGK974-mediated Wnt pathway suppression as a potential non-surgical treatment avenue, with sex-specific molecular responses and minimal impact on osteoclast function.

7917 records 5/528 page Previous Next 12345 下5页 Last page